Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy  of Patients with CLL with Mutated IGHV and Without Deletion 17p

Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Nitin Jain, Philip Thompson, Jan Burger, Gautam Borthakur, Prithviraj Bose, Zeev Estrov, Alessandra Ferrajoli, Koichi Takahashi, Naveen Garg, Xuemei Wang, Varsha Gandhi, William Plunkett, Rashmi Kanagal-Shamanna, Keyur Patel, Wanda Lopez, Hagop Kantarjian, Susan O'Brien, Michael Keating, William Wierda

Source: Clinical Lymphoma Myeloma and Leukemia - October 11, 2017 Category: Cancer & Oncology Source Type: research